Tumor Vasculature is Regulated by PHD2-mediated Angiogenesis and Bone Marrow-derived Cell Recruitment

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2009 May 30

PMID 19477431

Citations 105

Authors

Denise A Chan

Tiara L A Kawahara

Patrick D Sutphin

Howard Y Chang

Jen-Tsan Chi

Amato J Giaccia

Affiliations

Soon will be listed here.

Abstract

Sustained angiogenesis, through either local sprouting (angiogenesis) or the recruitment of bone marrow-derived cells (BMDCs) (vasculogenesis), is essential to the development of a tumor. How BMDCs are recruited to the tumor and their contribution to the tumor vasculature is poorly understood. Here, we demonstrate that both IL-8 and angiogenin contribute to the complementary pathways of angiogenesis and BMDC mobilization to increase tumor growth. These two factors are regulated by PHD2 in a HIF-independent but NF-kappaB-dependent manner. PHD2 levels are decreased in human cancers, compared with corresponding normal tissue, and correlate with an increase in mature blood vessels. Thus, PHD2 plays a critical role in regulating tumor angiogenesis.

Citing Articles

Blastocyst-Derived Lactate as a Key Facilitator of Implantation.

Gurner K, Gardner D Biomolecules. 2025; 15(1).

PMID: 39858494 PMC: 11764449. DOI: 10.3390/biom15010100.

Non-canonical Function of Prolyl Hydroxylase Domain 2 in Breast Cancer Cell Growth and Progression: Role of Peptidyl-prolyl Cis-trans Isomerase NIMA-interacting 1.

Guillen-Quispe Y, Kim S, Saeidi S, Choi G, Chelakkot C, Zhou T J Cancer Prev. 2025; 29(4):129-139.

PMID: 39790223 PMC: 11706723. DOI: 10.15430/JCP.24.031.

The Role of Salivary Vascular Endothelial Growth Factor A, Cytokines, and Amino Acids in Immunomodulation and Angiogenesis in Breast Cancer.

Sarf E, Dyachenko E, Belskaya L Biomedicines. 2024; 12(6).

PMID: 38927536 PMC: 11201966. DOI: 10.3390/biomedicines12061329.

Mechanisms of angiogenesis in tumour.

Zhang R, Yao Y, Gao H, Hu X Front Oncol. 2024; 14:1359069.

PMID: 38590656 PMC: 10999665. DOI: 10.3389/fonc.2024.1359069.

Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma.

Luomala L, Mattila K, Vainio P, Nisen H, Pellinen T, Lohi J Cancer Med. 2024; 13(3):e6998.

PMID: 38400673 PMC: 10891444. DOI: 10.1002/cam4.6998.

References

RYAN H, Poloni M, McNULTY W, Elson D, Gassmann M, Arbeit J . Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 2000; 60(15):4010-5. View

Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr W . Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002; 1(3):237-46. DOI: 10.1016/s1535-6108(02)00043-0. View

Mahon P, Hirota K, Semenza G . FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15(20):2675-86. PMC: 312814. DOI: 10.1101/gad.924501. View

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

RYAN H, Lo J, Johnson R . HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998; 17(11):3005-15. PMC: 1170640. DOI: 10.1093/emboj/17.11.3005. View

Ohh M, Park C, Ivan M, Hoffman M, Kim T, Huang L . Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000; 2(7):423-7. DOI: 10.1038/35017054. View

Pawitan Y, Bjohle J, Amler L, Borg A, Egyhazi S, Hall P . Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005; 7(6):R953-64. PMC: 1410752. DOI: 10.1186/bcr1325. View

Mori S, Rempel R, Chang J, Yao G, Lagoo A, Potti A . Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res. 2008; 68(20):8525-34. PMC: 3617051. DOI: 10.1158/0008-5472.CAN-08-1329. View

Chan D, Sutphin P, Yen S, Giaccia A . Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol. 2005; 25(15):6415-26. PMC: 1190339. DOI: 10.1128/MCB.25.15.6415-6426.2005. View

10.

Fett J, Strydom D, Lobb R, Alderman E, BETHUNE J, Riordan J . Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985; 24(20):5480-6. DOI: 10.1021/bi00341a030. View

11.

Kaelin W . Von Hippel-Lindau disease. Annu Rev Pathol. 2007; 2:145-73. DOI: 10.1146/annurev.pathol.2.010506.092049. View

12.

Semenza G . Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med. 2002; 41(2):79-83. DOI: 10.2169/internalmedicine.41.79. View

13.

Minamishima Y, Moslehi J, Bardeesy N, Cullen D, Bronson R, Kaelin Jr W . Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2007; 111(6):3236-44. PMC: 2265460. DOI: 10.1182/blood-2007-10-117812. View

14.

Gao D, Nolan D, Mellick A, Bambino K, McDonnell K, Mittal V . Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008; 319(5860):195-8. DOI: 10.1126/science.1150224. View

15.

Zhong H, De Marzo A, Laughner E, Lim M, Hilton D, Zagzag D . Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59(22):5830-5. View

16.

Carmeliet P . Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000; 6(4):389-95. DOI: 10.1038/74651. View

17.

Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H . Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res. 2006; 12(4):1080-7. DOI: 10.1158/1078-0432.CCR-05-2022. View

18.

Harris A . Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38-47. DOI: 10.1038/nrc704. View

19.

Garkavtsev I, Kozin S, Chernova O, Xu L, Winkler F, Brown E . The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature. 2004; 428(6980):328-32. DOI: 10.1038/nature02329. View

20.

Appelhoff R, Tian Y, Raval R, Turley H, Harris A, Pugh C . Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004; 279(37):38458-65. DOI: 10.1074/jbc.M406026200. View